Prime Medicine (PRME) Receivables - Net (2024 - 2025)
Prime Medicine's (PRME) quarterly Receivables - Net came in at $4.6 million in Q4 2025, up 185.02% YoY from $1.6 million in Q4 2024, and up 3721.67% on a QoQ basis from $120000.0 in Q2 2025.
Prime Medicine (PRME) Receivables - Net (2024 - 2025) Analysis & Trends
Prime Medicine (PRME) has 2 years of Receivables - Net data on file, last reported at $4.6 million in Q4 2025.
- Quarterly Receivables - Net rose 185.02% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (up 185.02% YoY) and the FY2025 annual result came in at $4.6 million, up 185.02% from the prior year.
- Receivables - Net grew to $4.6 million in Q4 2025, from $120000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $55.0 million in Q3 2024 to a low of $17000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.59 Mn |
| Dec 31, 2025 | 4.59 Mn |
| Jun 30, 2025 | 120,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Dec 31, 2024 | 1.61 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 55.00 Mn |
| Sep 30, 2024 | 55.00 Mn |